Scholar Rock (SRRK) to Release Earnings on Tuesday

Scholar Rock (NASDAQ:SRRK) is projected to post its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect Scholar Rock to post earnings of ($0.60) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Scholar Rock Stock Up 0.1 %

SRRK opened at $34.60 on Monday. The stock has a market cap of $3.28 billion, a PE ratio of -14.72 and a beta of 0.59. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock has a 52 week low of $6.76 and a 52 week high of $46.98. The business’s fifty day simple moving average is $39.46 and its 200 day simple moving average is $31.50.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Wedbush restated an “outperform” rating and issued a $47.00 price objective on shares of Scholar Rock in a report on Wednesday, January 29th. HC Wainwright lifted their target price on shares of Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Finally, Truist Financial boosted their price objective on shares of Scholar Rock from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, November 25th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Scholar Rock currently has a consensus rating of “Buy” and a consensus price target of $40.43.

Insiders Place Their Bets

In other Scholar Rock news, insider Mo Qatanani sold 68,510 shares of Scholar Rock stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $37.40, for a total transaction of $2,562,274.00. Following the transaction, the insider now directly owns 111,084 shares of the company’s stock, valued at $4,154,541.60. The trade was a 38.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Edward H. Myles sold 142,292 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $35.62, for a total transaction of $5,068,441.04. Following the completion of the sale, the chief financial officer now directly owns 111,345 shares in the company, valued at $3,966,108.90. This trade represents a 56.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 292,266 shares of company stock valued at $10,996,151. Insiders own 19.20% of the company’s stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.